FibroBiologics, Inc.
FBLG
$1.06
-$0.09-7.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.02% | -23.12% | -23.90% | 5.14% | 8.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.18% | 11.85% | -30.23% | 50.30% | 39.27% |
| Operating Income | 10.18% | -11.85% | 30.23% | -50.30% | -39.27% |
| Income Before Tax | 11.61% | -0.68% | -4.68% | -1,055.60% | -618.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.61% | -0.68% | -4.68% | -1,055.60% | -618.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.61% | -0.68% | -4.68% | -1,055.60% | -618.71% |
| EBIT | 10.18% | -11.85% | 30.23% | -50.30% | -39.27% |
| EBITDA | 10.45% | -11.70% | 31.13% | -50.06% | -39.00% |
| EPS Basic | 72.78% | 51.07% | 40.64% | -799.17% | -518.34% |
| Normalized Basic EPS | 72.78% | 51.07% | 40.64% | -799.23% | -518.38% |
| EPS Diluted | 72.78% | 51.07% | 40.64% | -799.17% | -518.34% |
| Normalized Diluted EPS | 72.78% | 51.07% | 40.64% | -799.23% | -518.38% |
| Average Basic Shares Outstanding | 224.70% | 105.75% | 76.33% | 28.51% | -94.38% |
| Average Diluted Shares Outstanding | 224.70% | 105.75% | 76.33% | 28.51% | -94.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |